Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001558370-20-011697
Filing Date
2020-10-23
Accepted
2020-10-23 17:01:37
Documents
12
Period of Report
2020-06-07
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K/A plx-20200607x8ka.htm   iXBRL 8-K/A 34457
  Complete submission text file 0001558370-20-011697.txt   155121

Data Files

Seq Description Document Type Size
2 EX-101.SCH plx-20200607.xsd EX-101.SCH 3248
3 EX-101.LAB plx-20200607_lab.xml EX-101.LAB 16112
4 EX-101.PRE plx-20200607_pre.xml EX-101.PRE 10896
5 EXTRACTED XBRL INSTANCE DOCUMENT plx-20200607x8ka_htm.xml XML 4818
Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401 972-4-988-9488
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-33357 | Film No.: 201258346
SIC: 2836 Biological Products, (No Diagnostic Substances)